The $4.6 billion final close of Blackstone Life Sciences V was not only oversubscribed -- it was also the largest life sciences private fund to be raised to date, according to Blackstone officials.
The firm said it has already invested and committed nearly $1 billion from the fund over the past three months, including deals with Alnylam, Reata Pharmaceuticals and Continue Reading Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
